AI-generated content for informational purposes only. Not financial advice. Always do your own research.

Om

Globalt medisinsk utstyrselskap spesialisert innen ortopedisk leddprotese, ryggkirurgi og tannimplantater. Aldring av befolkningen driver etterspørselen etter leddproteser.

Aksjer knyttet til aldrende befolkning

Zimmer Biomet spesialiserer seg i ortopedisk leddutskifting, ryggkirurgi og dentalimplantat, og nyter direkte godt av demografi med aldrende befolkning som driver økt volum av kirurgiske prosedyrer.

Key Financials ZBH

Pris $96.45
Endring (1D) +1.33%
Endring (30D) +7.26%
Endring (60D) +8.81%
Endring (90D) -2.41%
Endring (180D) +4.51%
Endring (1Y) -2.57%
Endring (5Y) -37.58%
P/E-forhold 8.96
EPS (TTM) $10.77
52-ukers rekkevidde $84.59 — $114.44
50-dagers MA $90.36
Volum 1.96M

Data updated Feb 15 · Source: Twelve Data

4.2
1 reviews
Demographic Exposure
4.8
Growth Potential
3.5
Dividend Reliability
3.5
Regulatory Risk
3.2
Financial Stability
3
Claude Opus 4.6
AI Review
4.2/5

Zimmer Biomet is a global leader in musculoskeletal healthcare, specializing in joint replacement implants (knees, hips, shoulders) " a market directly tied to aging demographics. The company is well-positioned as global populations age and demand for orthopedic procedures grows steadily.

The bull case is compelling: ZBH trades at a remarkably low P/E of 8.96 with strong EPS of $10.77, suggesting significant undervaluation relative to its defensive healthcare positioning. The stock sits well below its 52-week high of $114.44, offering potential upside. Recent momentum is positive, with a 7.26% gain over 30 days and price above the 50-day moving average.

However, the bear case is notable. The stock has lost 37.58% over five years, reflecting persistent concerns around execution challenges, competitive pressure from Stryker and Smith+Nephew, and integration issues from the 2015 Biomet merger. Debt levels remain elevated, and surgical volume recovery post-COVID has been uneven.

For aging population investors, Zimmer Biomet offers strong demographic tailwinds and an attractive valuation, but operational improvement must materialize to unlock value. The current discount may represent opportunity for patient investors.

Demographic Exposure
4.8
Dividend Reliability
3.5
Growth Potential
3.5
Regulatory Risk
3.2
Financial Stability
3
Feb 15, 2026
Zimmer Biomet Screenshot

Added: Feb 15, 2026

zimmerbiomet.com

Latest from Otrai